2009-11-16 15:00:08 -

BAGSVÆRD, DENMARK -- (Marketwire) -- 11/16/09 -- On 7 August 2009 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.



On 7 August 2009 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.



Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 2.4 billion in the period from 10 August 2009 to 18 December 2009.



Since the announcement as of 9 November 2009, the following transactions have been made under the programme:

                  Number of    Average     Transaction value,
                   shares   purchase price        DKK
Accumulated, last
announcement      5,089,099                     1,625,077,813
9 November 2009      75,000       323.2516         24,243,870
10 November 2009     75,000       321.9600         24,147,000
11 November 2009     75,000       324.9821         24,373,658
12 November 2009     75,000       326.2050         24,465,375
13 November 2009     75,000       326.5990         24,494,925
Accumulated under
the programme     5,464,099                     1,746,802,641

Transactions related to Novo Nordisk's incentive programmes have resulted in a net sale by Novo Nordisk of 33,500 B shares in the period from 9 November 2009 to 13 November 2009. The shares in these transactions were not part of the Safe Harbour repurchase programme.



With the transactions stated above, Novo Nordisk owns a total of 30,180,477 treasury shares, corresponding to 4.9% of the share capital. The total amount of shares in the company is 620,000,000 including treasury shares.



Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 29,000 employees in 81 countries, and markets its products in 179 countries.
Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.

Further information:



Media:                 Investors:



Elin K Hansen          Mads Veggerby Lausten
Tel: (+45) 4442 3450   Tel: (+45) 4443 7919
 ekh@novonordisk.com : mailto:ekh@novonordisk.com      mlau@novonordisk.com : mailto:mlau@novonordisk.com 



                       Kasper Roseeuw Poulsen
                       Tel: (+45) 4442 4471
                        krop@novonordisk.com : mailto:krop@novonordisk.com 



In North America:      In North America:
Sean Clements          Hans Rommer
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937
 secl@novonordisk.com : mailto:secl@novonordisk.com     hrmm@novonordisk.com : mailto:hrmm@novonordisk.com 

Company Announcement no 68 / 2009


This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.



Copyright © Hugin AS 2009. All rights reserved.

Further information:

Media:

Elin K Hansen
Tel: (+45) 4442 3450
ekh@novonordisk.com :

In North America:
Sean Clements
Tel: (+1) 609 514 8316
secl@novonordisk.com :

Investors:

Mads Veggerby Lausten
Tel: (+45) 4443 7919
mlau@novonordisk.com :

Kasper Roseeuw Poulsen
Tel: (+45) 4442 4471
krop@novonordisk.com :

In North America:
Hans Rommer
Tel: (+1) 609 919 7937
hrmm@novonordisk.com :